Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 1Endocrine 1CNS 1

Conditions

Prostatic Hyperplasia 1Pheochromocytoma 1Paraganglioma 1Lower Urinary Tract Symptoms 1

Interventions

Cyclophosphamide 548pembrolizumab 384Radiotherapy 363Bevacizumab 360Carboplatin 351Rituximab 315Cisplatin 300Gemcitabine 297Paclitaxel 288Dexamethasone 272Docetaxel 271fludarabine phosphate 241Doxorubicin 231Nivolumab 220Etoposide 209Cytarabine 203Lenalidomide 201fludarabine 191Oxaliplatin 191Fluorouracil 190Melphalan 189Filgrastim 188Capecitabine 175Calcium Dobesilate 172Radiosurgery 167Erlotinib Hydrochloride 167Methotrexate 163Bortezomib 162Granulocyte Colony-Stimulating Factor 154Whole-Body Irradiation 144

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Has results × Doxazosin × Clear all
NCT03176693 2023-11-20

Preoperative Alpha Blockade for Pheochromocytoma

University of California, Los Angeles

Phase 3 Completed
39 enrolled 8 charts
CNSEndocrine

Paraganglioma, Pheochromocytoma

NCT01678313 2014-07-15

Cyclooxygenase-2 (COX-2) Inhibitor Reduces Serum Prostatic Specific Antigen (PSA) Levels

Buddhist Tzu Chi General Hospital

Phase 2 Completed
140 enrolled 10 charts
Genitourinary

Prostatic Hyperplasia, Lower Urinary Tract Symptoms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡